Journal Article

Global distribution of TEM-1 and ROB-1 β-lactamases in <i>Haemophilus influenzae</i>

D. J. Farrell, I. Morrissey, S. Bakker, S. Buckridge and D. Felmingham

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 56, issue 4, pages 773-776
Published in print October 2005 | ISSN: 0305-7453
Published online August 2005 | e-ISSN: 1460-2091 | DOI:
Global distribution of TEM-1 and ROB-1 β-lactamases in Haemophilus influenzae

Show Summary Details


Objectives: To determine the global distribution of TEM-1 and ROB-1 β-lactamases in Haemophilus influenzae isolated from patients with community-acquired respiratory tract infection during the first 4 years of the PROTEKT study (1999–2003). To investigate the activities of commonly used antibiotics against these isolates.

Methods: For 14 870 H. influenzae, MIC testing was performed using NCCLS broth microdilution methodology. For 2225 β-lactamase-positive (BLP) H. influenzae, TEM-1 and ROB-1 genes were detected using a Taqman PCR method.

Results: β-Lactamase positivity was 15.0% overall but varied greatly by country (<5% in several countries to 67.9% in Taiwan). Prevalences of TEM-1 and ROB-1 BLP H. influenzae were 93.7% and 4.6%, respectively, however almost all ROB-1 isolates were found in Canada, the USA and Mexico. ROB-1 isolates (n = 102) were less susceptible against cefaclor (29.4% versus 87.6%) and cefprozil (42.2% versus 91.9%) than TEM-1 (n = 2085) isolates. Differences in susceptibility rates for chloramphenicol, co-trimoxazole and tetracycline were also found between the two groups.

Conclusions: The ROB-1 β-lactamase was found almost exclusively in North America and was more active against cefaclor and cefprozil than the TEM-1 β-lactamase.

Keywords: surveillance; resistance genes; cefaclor; cefprozil

Journal Article.  1505 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.